Comparative analysis of deferasirox and deferiprone iron chelator on the growth pattern of Bengali β-thalassemia major children of West Bengal, India

Comparative analysis of deferasirox and deferiprone iron chelator on the growth pattern of Bengali β-thalassemia major children of West Bengal, India

Background: Ineffective erythropoiesis and excessive red blood cell transfusions are the major source of iron overload in case of thalassemia major patients. It is mainly accountable for the growth retardation, morbidity, and mortality in patients with beta thalassemia major. The availability of eff...

Full description

Bibliographic Details
Main Authors:	Isita Tripathy, Amrita Panja, Rajarshi Basu
Format:	Article
Language:	English
Published:	Manipal College of Medical Sciences, Pokhara 2022-09-01
Series:	Asian Journal of Medical Sciences
Subjects:	β-thalassemia major; deferasirox; deferiprone; height; weight velocity
Online Access:	https://www.nepjol.info/index.php/AJMS/article/view/44491

Similar Items

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
by: Shahla Ansari, et al.
Published: (2017-06-01)

ANALYSIS OF DEFERASIROX AND DEFERIPRON USE IN CHILDREN WITH PEDIATRIC -THALASSEMIA MAJOR
by: Evy Sari Sutrisnaningsih, et al.
Published: (2017-08-01)

Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major
by: Hossein Karami, et al.
Published: (2017-01-01)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
by: Kontoghiorghe CN, et al.
Published: (2016-01-01)

IRON CHELATION THERAPY IN THALASSEMIA SYNDROMES
by: Paolo Cianciulli
Published: (2009-06-01)

Challenges of Iron Chelation in Thalassemic Children
by: Alkistis Adramerina, et al.
Published: (2024-02-01)

Treatment Status of Patients with Β-Thalassemia Major in Northern Iran: Thalassemia Registry System
by: Mehrnoush KOSARYAN, et al.
Published: (2019-07-01)

The COST-UTILITY ANALYSIS OF FOUR CHELATION REGIMENS FOR Β-THALASSEMIA MAJOR: A CHINESE PERSPECTIVE
by: Jialian Li
Published: (2020-04-01)

Side effect of deferiprone as iron chelator in patient with thalassemia
by: Mikhael Yosia, et al.
Published: (2018-01-01)

ECONOMIC EVALUATION OF CHELATION REGIMENS FOR β--THALASSEMIA MAJOR: A SYSTEMATIC REVIEW
by: Jialian Li
Published: (2019-06-01)

Iron Chelator Drugs in Transfusion Dependent Thalassemia: a Review
by: M Hashemieh
Published: (2020-08-01)

The Best Iron Chelation Therapy in Major Thalassemia Patients is Combination of Desferrioxamine and Deferiprone
by: Ebrahim miri moghaddam, et al.
Published: (2011-04-01)

The Best Iron Chelation Therapy in Major Thalassemia Patients is Combination of Desferrioxamine and Deferiprone
by: Mohammad Ali Mashhadi, et al.
Published: (2011-06-01)

Efficacy of defroxamine- deferiprone on cardiac function of patients with major thalassemia
by: Mirbehbahani NB, et al.
Published: (2015-09-01)

Pengaruh Deferasirox Terhadap Kadar T4 dan TSH Pada B-Thalassemia Mayor dengan Kadar Ferritin Tinggi
by: Dewi Ratih P, et al.
Published: (2016-11-01)

Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives
by: Bayanzay K, et al.
Published: (2016-08-01)

Antioxidant Activity of Deferasirox and Its Metal Complexes in Model Systems of Oxidative Damage: Comparison with Deferiprone
by: Viktor A. Timoshnikov, et al.
Published: (2021-08-01)

Development of Thalassemia Medication Questionnaire (TMQ): An Instrument for Measuring Major Thalassemia Patients’ Knowledge and Practice Regarding their Medications
by: Azita Azarkeivan, et al.
Published: (2022-12-01)

Renal function in patients with thalassemia major receiving Exjade® dispersible tablets and a new film-coated tablet formulation of deferasirox (Nanojade®)
by: Vahid Falahati, et al.
Published: (2022-01-01)

Comparative Efficacy of Deferiprone, Deferoxamine and Combination of Deferiprone and Deferoxamine on Serum Ferritin Value in Beta-Thalassemia Patients
by: Nargesbeygom Mirbehbahani, et al.
Published: (2015-01-01)

THE ANTIOXIDANT EFFECTS OF CAPPARIS OVATA AND DEFERASIROX IN PATIENTS WITH THALASSEMIA MAJOR
by: Handan Duman, et al.
Published: (2014-08-01)

Assessment of the effect of combination therapy with Deferiprone & Desferrioxamine on cardiac complications in major Thalassemia
by: F. Rashidi ghader, M.D, et al.
Published: (2007-01-01)

Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major
by: Nuzzi R, et al.
Published: (2021-05-01)

Differences between the European Union and United States of America in Drug Regulatory Affairs Affect Global Patient Safety Standards and Public Health Awareness: The Case of Deferasirox and Other Iron Chelating Drugs
by: George J. Kontoghiorghes
Published: (2021-07-01)

Comparison of the effects of deferasirox film-coated tablets (Jadenu®) and deferasirox dispersible tablets (Exjade®) in patients with beta thalassemia major: a preliminary report of the effects on the satisfaction, convenience, cardiac/liver MRI T2*, serum ferritin level, and biochemical profiles
by: Mahya Mobinikhaledi, et al.
Published: (2024-11-01)

Advances in iron chelation therapy: transitioning to a new oral formulation
by: Nirmish R Shah
Published: (2017-06-01)

Chelation Combination—A Strategy to Mitigate the Neurotoxicity of Manganese, Iron, and Copper?
by: Jan O. Aaseth, et al.
Published: (2022-11-01)

Lens opacity as a serious side effect following chelation therapy in beta thalassemia: A comparison between deferoxamine and deferasirox; randomized double-blinded clinical trial
by: Mohammad Reza Golpayegani, et al.
Published: (2019-01-01)

Adherence to Iron Chelation Therapy and Its Determinants
by: Sukhmani Sidhu, et al.
Published: (2021-01-01)

Comparison of the Mean Serum Ferritin Levels in Thalassaemia Major Patients after Giving Deferasirox and Deferoxamine
by: Seema Aftab, et al.
Published: (2017-12-01)

Sex and Gender Differences in Iron Chelation
by: Sarah Allegra, et al.
Published: (2024-12-01)

Comparison of deferasirox and deferoxamine effect on liver enzyme activities and ferritin level in patients with beta-thalassemia
by: Rasul Jameel Ali, et al.
Published: (2020-12-01)

Recent developments centered on orally active iron chelators
by: Robert Hider
Published: (2014-09-01)

Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes [version 2; peer review: 2 approved]
by: Khairunnisa Khairunnisa, et al.
Published: (2023-12-01)

Assessing the auditory effects of oral chelation therapy drug Deferasirox in individuals with β‐thalassemia major
by: Balwinder S. Tiwana, et al.
Published: (2024-12-01)

Use of Deferasirox Film-Coated Tablets in Pediatric Patients with Transfusion Dependent Thalassemia: A Single Center Experience
by: Alkistis Adramerina, et al.
Published: (2022-02-01)

LONG-TERM EFFECTIVENESS, SAFETY, AND TOLERABILITY OF TWICE-DAILY DOSING WITH DEFERASIROX IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSEMIAS UNRESPONSIVE TO STANDARD ONCE-DAILY DOSING
by: Jassada Buaboonnam, et al.
Published: (2021-10-01)

DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
by: Ali Taher
Published: (2018-11-01)

Duodenal perforation caused by deferasirox “case report”
by: Mohammmed Al Blooshi, et al.
Published: (2023-07-01)

Stable Luminescent Poly(Allylaminehydrochloride)-Templated Copper Nanoclusters for Selectively Turn-Off Sensing of Deferasirox in β-Thalassemia Plasma
by: Hung-Ju Lin, et al.
Published: (2021-12-01)